Morgan Stanley upgrades Bouygues stock to Equalweight on Equans margin outlook

Morgan Stanley has upgraded Bouygues SA to Equalweight from Underweight, raising its price target to EUR44.00 from EUR36.00. This positive revision is driven by expectations that Bouygues’ Equans division will exceed its 2025 and 2027 margin guidance, forecasting ROPA margins of 4.2% and 5% respectively, and outperform on free cash flow. The firm projects a 12% EBIT CAGR for 2026-2028, double that of peers, which is expected to provide approximately EUR3 per share in annual value accretion and establish a solid floor for the stock.

Analysis

Morgan Stanley has upgraded Bouygues SA to Equalweight from Underweight, raising its price target by over 22% to EUR44.00 from EUR36.00. The revision is fundamentally driven by a more optimistic outlook for the company's Equans division, which is now expected to surpass its 2025 and 2027 margin guidance. The bank projects Equans will achieve a Return on Operating Profit (ROPA) margin of approximately 4.2% in 2025 and 5% in 2027, coupled with superior free cash flow generation due to improved contract quality and lower restructuring costs. Critically, Morgan Stanley's analysis suggests the quality perception gap between Equans and its primary peers has substantially closed. The firm forecasts a 12% EBIT Compound Annual Growth Rate (CAGR) for Bouygues between 2026 and 2028, a rate double that of its competitors. This superior growth profile is anticipated to create about EUR3 per share in annual value accretion, establishing a solid valuation floor for the stock.

Key Decisions for Investors

• Given the upgrade to Equalweight and a higher price target, investors should recognize the improved fundamental outlook for the Equans division, which now provides a stronger valuation floor for Bouygues.
• The projected 12% EBIT CAGR, double that of peers, suggests Bouygues may warrant a re-rating, but the 'Equalweight' stance implies the stock may be approaching fair value at the new target, cautioning against overly aggressive new long positions.
• Investors should closely monitor the quarterly performance of the Equans division, specifically tracking ROPA margins and free cash flow conversion to validate Morgan Stanley's thesis of sustained outperformance.